480 related articles for article (PubMed ID: 22575984)
1. Leishmaniasis: current status of available drugs and new potential drug targets.
Singh N; Kumar M; Singh RK
Asian Pac J Trop Med; 2012 Jun; 5(6):485-97. PubMed ID: 22575984
[TBL] [Abstract][Full Text] [Related]
2. Challenges and new discoveries in the treatment of leishmaniasis.
Singh S; Sivakumar R
J Infect Chemother; 2004 Dec; 10(6):307-15. PubMed ID: 15614453
[TBL] [Abstract][Full Text] [Related]
3. Current treatment approaches to leishmaniasis.
Berman J
Curr Opin Infect Dis; 2003 Oct; 16(5):397-401. PubMed ID: 14501991
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
5. Leishmaniasis: an update of current pharmacotherapy.
Sundar S; Chakravarty J
Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
[TBL] [Abstract][Full Text] [Related]
6. Liposomal formulations in the pharmacological treatment of leishmaniasis: a review.
Ortega V; Giorgio S; de Paula E
J Liposome Res; 2017 Sep; 27(3):234-248. PubMed ID: 28874072
[TBL] [Abstract][Full Text] [Related]
7. Clinical status of agents being developed for leishmaniasis.
Berman J
Expert Opin Investig Drugs; 2005 Nov; 14(11):1337-46. PubMed ID: 16255674
[TBL] [Abstract][Full Text] [Related]
8. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
Singh N; Chatterjee M; Sundar S
Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
[TBL] [Abstract][Full Text] [Related]
9. The treatment of visceral leishmaniasis: safety and efficacy.
Jha RK; Sah AK; Shah DK; Sah P
JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous leishmaniasis treatment.
Minodier P; Parola P
Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
[TBL] [Abstract][Full Text] [Related]
11. Drug combinations for visceral leishmaniasis.
Olliaro PL
Curr Opin Infect Dis; 2010 Dec; 23(6):595-602. PubMed ID: 20871400
[TBL] [Abstract][Full Text] [Related]
12. Challenges in the management of visceral leishmaniasis.
Sundar S; Kumar A
Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268
[No Abstract] [Full Text] [Related]
13. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
14. Advances in the treatment of leishmaniasis.
Sundar S; Rai M
Curr Opin Infect Dis; 2002 Dec; 15(6):593-8. PubMed ID: 12821836
[TBL] [Abstract][Full Text] [Related]
15. Treatment of visceral leishmaniasis.
Sundar S
Med Microbiol Immunol; 2001 Nov; 190(1-2):89-92. PubMed ID: 11770119
[TBL] [Abstract][Full Text] [Related]
16. Development of new antileishmanial drugs--current knowledge and future prospects.
Le Pape P
J Enzyme Inhib Med Chem; 2008 Oct; 23(5):708-18. PubMed ID: 18671165
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of leishmaniasis: past, present and future.
Mishra J; Saxena A; Singh S
Curr Med Chem; 2007; 14(10):1153-69. PubMed ID: 17456028
[TBL] [Abstract][Full Text] [Related]
18. Promising therapeutic targets for antileishmanial drugs.
Werbovetz KA
Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
[TBL] [Abstract][Full Text] [Related]
19. Protease inhibitors in potential drug development for Leishmaniasis.
Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
[TBL] [Abstract][Full Text] [Related]
20. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
